Tags : P-III 1489


Gilead Reports Results of Biktarvy for the Treatment of HIV-1

 Shots: The P-III 1489 study has assessed Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in ratio (1:1) to treat HIV-1 infection in adults for 96 weeks, testing safety and efficacy P-III 1489 study results ((abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) or Biktarvy): meGFR @96wks. (-7.8 mL/min vs. -9.6 mL/min); mean percent changes from baseline in […]Read More